The champion-driven sales motion that built B2B SaaS doesn't translate to DSOs. In a DSO, the buyer is rarely one person — it's at least four. A clinical lead wants better workflows. An ops leader wants standardization. IT wants to not get fired. Finance wants to know what this looks like in year three.
Your sales team has built a relationship with the first one. The other three enter the deal in the final six weeks and ask questions the champion can't answer. The deal stalls. Someone in the QBR calls it pipeline hygiene.
It isn't pipeline hygiene. It's a buying-committee mismatch — and it's the single most common failure pattern we see in dental vendor pipelines.
What the bad version looks like
The clinical lead is dazzled by the demo. Forwards the deck to ops a month in. Ops asks who handles the rollout. The vendor says "we have a customer success team." Ops reads that as "no one." The deal moves to next quarter. Then to next year. Then to a closed-lost note no one revisits.
Three questions every dental vendor should pressure-test their GTM against
- Who actually signs? Not the champion. Who has authority to commit budget across all locations? If you can't name that person inside the first three calls, you're selling into a maze.
- Who handles the rollout, by name? "Our implementation team" is not a name. Dental buyers have been burned. They want a person, a methodology, and a timeline. Vague answers at proposal stage kill more deals than pricing does.
- What's the adoption metric, and who owns it? If your contract ends at go-live, your renewal ends at month eighteen. Build adoption into the deal, or watch NRR erode every quarter.
What changes when you fix this
Early-stage deals get longer. Late-stage deals get shorter. The ratio inverts. You spend more time scoping the buying committee and the implementation plan up front, and less time defending pricing in week eleven against objections you could have surfaced in week two.
The deal doesn't close at signature. It closes when the platform gets used.
That's the only kind of deal worth closing — and the kind that builds the reference customers you'll sell with for the next three years.
Want this analysis for your organization? Explore Industry Intelligence →